Adaptin Bio (APTN) Common Equity (2022 - 2026)

Adaptin Bio (APTN) has 5 years of Common Equity data on file, last reported at -$1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 201.74% year-over-year to -$1.8 million; the trailing twelve-month figure through Mar 2026 stood at -$1.8 million (down 201.74% YoY), and the FY2025 full-year result was -$1.5 million, up 63.67% from the prior year.
• Common Equity slipped to -$1.8 million in Q1 2026, from -$1.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.7 million in Q1 2025 to a low of -$4.1 million in Q4 2024.
• A 5-year average of -$1.2 million and a median of -$1.1 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 4018.87% in 2024 and soared 232.52% in 2025, its largest moves.
• Tracing APTN's Common Equity over 5 years: stood at -$27304.0 in 2022, then sank by 3480.28% to -$977559.0 in 2023, then sank by 319.42% to -$4.1 million in 2024, then jumped by 63.67% to -$1.5 million in 2025, then dropped by 19.21% to -$1.8 million in 2026.
• Business Quant data shows APTN's Common Equity at -$1.8 million in Q1 2026, -$1.5 million in Q4 2025, and -$881078.0 in Q3 2025.